Labcorp agreed to acquire BioReference’s laboratory testing operations in a $722 million cash deal designed to extend national reach for specialty diagnostics, including the FDA-approved 4Kscore blood test for assessing aggressive prostate cancer likelihood before biopsy. The transaction includes BioReference’s clinical and women’s health testing, urology and corrections services, and more than 80 additional patient service centers that will join Labcorp’s network. The agreement also includes an earnout of up to $150 million tied to 4Kscore revenue performance. Labcorp projected roughly $250 million in first-year revenue from the acquired business after closing, contingent on post-closing forecasts. In operational terms, both companies said services would remain unchanged until regulatory approvals and closing conditions are met. The deal is likely to matter to payers and providers focused on scaling risk stratification while maintaining logistics for patient-facing blood-based testing. For market participants, the strategic signal is that lab consolidators are doubling down on commercially validated companion-style diagnostics in urology, using physical patient service centers and lab network capacity to drive utilization.